• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Palvella Therapeutics Inc.

    4/30/26 4:11:39 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PVLA alert in real time by email
    DEFA14A 1 tm261617d3_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

     

     

    Filed by the Registrant x  
    Filed by a Party other than the Registrant ¨  

     

     Check the appropriate box:
    ¨ Preliminary Proxy Statement
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨ Definitive Proxy Statement
    x Definitive Additional Materials
    ¨ Soliciting Material under §240.14a-12

     

     

     

    PALVELLA THERAPEUTICS, INC.

    (Name of Registrant as specified in its Charter)

     

    N/A

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

     

     

     Payment of Filing Fee (Check all boxes that apply):
    x No fee required
    ¨ Fee paid previously with preliminary materials
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

    GRAPHIC

    www.investorvote.com/PVLA Step 1: Go to www.investorvote.com/PVLA. Step 2: Click on the icon on the right to view meeting materials. Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in. Online Go to www.investorvote.com/PVLA or scan the QR code — login details are located in the shaded bar below. Stockholder Meeting Notice 04997I Important Notice Regarding the Availability of Proxy Materials for the Palvella Therapeutics, Inc. Stockholder Meeting to be Held on June 10, 2026 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Proxy Statement and 10-K for fiscal year end December 31, 2025 are available at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 29, 2026 to facilitate timely delivery. 2NOT Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares.

    GRAPHIC

    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.investorvote.com/PVLA. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to investorvote@computershare.com with “Proxy Materials Palvella Therapeutics, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, requests for a paper copy of proxy materials must be received by May 29, 2026. Palvella Therapeutics, Inc. Annual Meeting of Stockholders will be held on June 10, 2026 virtually via the internet at https://meetnow.global/MZMQXWT at 11:00 AM EST. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommend a vote FOR all the nominees listed, FOR Proposals 2, 3, 5 and 6, and 1 YEAR on Proposal 4: 1. Election of three director nominees to serve as Class III directors whose term will expire in 2029: 01 - George M. Jenkins 02 - Todd C. Davis 03 - John Doux, M.D. 2. Ratification of the appointment of Ernst & Young as the Company’s independent registered public accounting firm for the 2026 fiscal year. 3. Approval, on an advisory basis, of the compensation of the Company’s named executive officers. 4. Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation paid to the Company’s named executive officers. 5. Approval of an amendment to the 2024 Equity Incentive Plan to increase the authorized shares issuable under the 2024 Plan by 750,000 shares. 6. Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you. Stockholder Meeting Notice

     

     

     

    Get the next $PVLA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PVLA

    DatePrice TargetRatingAnalyst
    5/12/2026$220.00Overweight
    Stephens
    1/7/2026$205.00Outperform
    Mizuho
    12/5/2025$167.00Buy
    BTIG Research
    12/4/2025$175.00Buy
    Craig Hallum
    11/19/2025$143.00Outperform → Strong Buy
    Raymond James
    9/9/2025$85.00Outperform
    Oppenheimer
    8/6/2025$54.00Outperform
    Raymond James
    7/21/2025$56.00Buy
    Truist
    More analyst ratings

    $PVLA
    SEC Filings

    View All

    Palvella Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    5/20/26 4:35:15 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    5/15/26 7:30:16 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    5/13/26 7:30:15 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jenkins George M bought $500,000 worth of shares (4,000 units at $125.00), increasing direct ownership by 2% to 187,171 units (SEC Form 4)

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    3/2/26 8:00:54 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Elaine J bought $300,000 worth of shares (2,400 units at $125.00), increasing direct ownership by 5% to 47,812 units (SEC Form 4)

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    3/2/26 8:00:10 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jenkins George M bought $100,797 worth of shares (4,990 units at $20.20), increasing direct ownership by 1% to 183,171 units (SEC Form 4)

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    4/10/25 7:06:12 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations

    Palvella remains on track to submit an NDA in the second half of 2026 Microcystic lymphatic malformations are serious, chronic, lifelong vascular malformations that can cause persistent leaking, bleeding, infection, functional impairment, and significant daily burden for patients and families QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and standard of care for the estimated more than 30,000 individuals with microcystic lymphatic malformations in the U.S. WAYNE, Pa., June 03, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing n

    6/3/26 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

    WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9, 2026 at 8:40 a.m. ET. A live webcast of the fireside chat will be available on the Events and Present

    6/2/26 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043

    Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in porokeratosis, including disseminated superficial actinic porokeratosis (DSAP) DSAP is a serious, rare, premalignant genetic skin disease affecting an estimated more than 50,000 diagnosed patients in the U.S., with no FDA-approved therapies Palvella plans to initiate a Phase 2 clinical trial of QTORIN™ pitavastatin in DSAP in the second half of 2026 WAYNE, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the "Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering f

    5/27/26 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Goin Kathleen exercised 4,302 shares at a strike of $8.11 and sold $475,631 worth of shares (4,302 units at $110.56) as part of a pre-agreed trading plan (SEC Form 4)

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    5/22/26 4:05:12 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Goin Kathleen

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    4/17/26 4:05:10 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Doux John

    3 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    4/15/26 4:05:11 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens initiated coverage on Palvella Therapeutics with a new price target

    Stephens initiated coverage of Palvella Therapeutics with a rating of Overweight and set a new price target of $220.00

    5/12/26 8:33:52 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Palvella Therapeutics with a new price target

    Mizuho initiated coverage of Palvella Therapeutics with a rating of Outperform and set a new price target of $205.00

    1/7/26 9:14:06 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Palvella Therapeutics with a new price target

    BTIG Research initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $167.00

    12/5/25 8:40:54 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Leadership Updates

    Live Leadership Updates

    View All

    Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors

    Physician and seasoned life sciences investor with more than two decades of experience across clinical practice, biotechnology investing, and board leadership Author of a visionary 2015 Journal of Investigative Dermatology editorial highlighting the need for greater innovation and investment in rare skin diseases Deep medical and patient care experience will help guide the continued expansion of Palvella's pipeline and QTORIN™ platform WAYNE, Pa., April 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or "the Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from ser

    4/13/26 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

    Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (NASDAQ:ARQT), where he led U.S. sales efforts for ZORYVE®, a next-generation topical PDE4 inhibitor; previously, he held leadership roles at Incyte (NASDAQ:INCY) supporting the launch of OPZELURA® Mr. Taylor to lead Palvella's U.S. sales organization in preparation for the potential U.S. launch of QTORIN™ rapamycin for microcystic lymphatic malformations, a serious, rare, lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. WAYNE, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Palvella Ther

    4/7/26 7:30:00 AM ET
    $ARQT
    $INCY
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

    Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (NASDAQ:KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from FDA approval in 2023 to $389 million in annual sales in 2025 Ms. McDonough to lead Palvella's Market Access and Patient Services organizations, advancing payer engagement, patient support, specialty distribution, and access strategy for the Company's QTORIN™ programs targeting serious, rare skin diseases and vascular malformations WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage biopharmaceut

    3/23/26 7:30:00 AM ET
    $KRYS
    $PVLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $PVLA
    Financials

    Live finance-specific insights

    View All

    Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026

    WAYNE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or "the Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will report its first quarter 2026 financial results before market open on Thursday, May 7, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update. To access the live webcast, includi

    4/30/26 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026

    WAYNE, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. ("Palvella" or "the Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the Company will report its full year 2025 financial results before market open on Tuesday, March 31, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update. To access the live webcast

    3/24/26 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

    Primary endpoint met with statistically significant improvement (mean change of +2.13; p<0.001) on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA) Achieved statistical significance on pre-specified key secondary endpoint (p<0.001) and all four secondary efficacy endpoints (all p<0.001) 95% of trial participants aged ≥ 6 who completed the efficacy evaluation period improved on the mLM-IGA at Week 24 86% of trial participants aged ≥ 6 who completed the efficacy evaluation period were rated as "Much Improved" (+2) or "Very Much Improved" (+3) on the mLM-IGA at Week 24 QTORIN™ rapamycin was well-tolerated, with no drug-related serious adverse events reported a

    2/24/26 6:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care